Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
SOURCE Analysts Review
Editor Note: For more information about this release, please scroll to bottom
NEW YORK, July 4, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding Alere Inc. (NYSE: ALR), Albany Molecular Research Inc. (NASDAQ: AMRI), Anika Therapeutics Inc. (NASDAQ: ANIK), Nektar Therapeutics (NASDAQ: NKTR) and Sangamo Biosciences Inc. (NASDAQ: SGMO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4465-100free.
Alere Inc. Analyst Notes
On July 1, 2014, Alere Inc. (Alere) announced the appointment of Chief Operating Officer Namal Nawana as interim CEO and President following the resignation of CEO, President and Director Ron Zwanziger, effective immediately. Additionally, the Company stated that the resignations of Jerry McAleer, Senior Vice President Research and Development and a Director, and Dave Scott, Chief Scientific Officer, are also effective immediately. Alere informed that these changes are a part of its ongoing review of strategy and operations. According to the Company, to identify a permanent CEO and President, its Board of Directors will initiate a search process which includes a review of both internal and external candidates and plans to retain a leading executive search firm. Alere Chairman of the Board, Gregg J. Powers, stated, "We believe that with Alere's talented management team in place, now is the right time for the Company to transition to new leadership." The full analyst notes on Alere are available to download free of charge at:
Albany Molecular Research Inc. Analyst Notes
On July 1, 2014, Albany Molecular Research Inc. (AMRI) announced its successful acquisition of Oso Biopharmaceuticals Manufacturing, a former portfolio company of Altaris Capital Partners, LLC, in line with its strategy to be the leading supplier of custom and complex drug product development and manufacturing services to the pharmaceutical industry. According to the Company, it has paid a total consideration of $110 million, funded through cash on hand. Additionally, AMRI stated that it plans to provide investors with an updated 2014 guidance for the combined company when it releases its Q2 2014 financial results on August 5, 2014. The full analyst notes on AMRI are available to download free of charge at:
Anika Therapeutics Inc. Analyst Notes
On July 1, 2014, Anika Therapeutics Inc.'s (Anika Therapeutics) stock increased by 4.73%, ending the day at $48.52. Over the past five-day trading period, Company's stock went up by 4.57% compared to the Nasdaq Composite which increased by 2.06% during the same trading period. The full analyst notes on Anika Therapeutics are available to download free of charge at:
Nektar Therapeutics Analyst Notes
On June 19, 2014, Nektar Therapeutics (Nektar) reported that its partner AstraZeneca announced that the New England Journal of Medicine (NEJM) has published results of two pivotal Phase III studies, KODIAC-4 and KODIAC-5 of Naloxegol, an investigational treatment for opioid-induced constipation (OIC). According to the Company, the Phase III studies KODIAC-4 and KODIAC-5 evaluated 12.5 mg and 25 mg doses of naloxegol, administered once a day, over 12-week, multicenter, randomised, double blind, placebo-controlled pivotal trials. Additionally, Nektar stated that Naloxegol has the potential to be the first FDA approved once-daily oral treatment for patients with OIC. William Chey, MD, AGAF, FACG, FACP, Professor of Medicine at the University of Michigan Health System, said, "These results demonstrated the potential for naloxegol, if approved, to be a new treatment option as the studies showed rapid and sustained improvement for these patients, without compromising their pain management over the course of the trials." The full analyst notes on Nektar are available to download free of charge at:
Sangamo Biosciences Inc. Analyst Notes
On June 19, 2014, Sangamo Biosciences Inc. (Sangamo) announced that the Company has appointed H. Stewart Parker to the Board of Directors. According to the Company, Parker founded and served as President and CEO of Targeted Genetics Corporation. Sangamo President and CEO, Edward Lanphier, stated, "We are very pleased to bring Stewart onto our Board during such an important stage in Sangamo's development. As we expand our manufacturing capabilities and advance ZFP Therapeutic® programs for the development of genetic cures for monogenic diseases, Stewart's proven entrepreneurial and executive leadership skills and extensive experience in AAV gene therapy, particularly cGMP manufacturing and clinical development, will be very valuable to Sangamo." The full analyst notes on Sangamo are available to download free of charge at:
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com .
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com .
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
©2012 PR Newswire. All Rights Reserved.